Profile: Ipca Laboratories Ltd (IPCA.BO)

IPCA.BO on Bombay Stock Exchange

817.85INR
23 Apr 2014
Price Change (% chg)

Rs21.35 (+2.68%)
Prev Close
Rs796.50
Open
Rs800.00
Day's High
Rs824.00
Day's Low
Rs799.00
Volume
18,662
Avg. Vol
16,090
52-wk High
Rs906.90
52-wk Low
Rs506.40

Search Stocks
IPCA Laboratories Limited is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 active pharmaceutical ingredients (APIs). The Company exports its APIs to the United States, Canada and South American countries and formulations to the United States, Panama, West Indies and South American countries. Its international client roster includes global pharmaceutical companies, such as AstraZeneca, GlaxoSmithKline, Merck, Roche and Sanofi Aventis. It is building its brand in chronic therapy segments, such as cardio-vascular, anti-diabetic, anti-malarias and non steroidal anti-inflammatory drugs (NSAID). During the fiscal year ended March 31, 2012 (fiscal 2012), the Company introduced five new products in the domestic market. The Company has formulation manufacturing unit at special economic zone coverage (SEZ) Indore. During fiscal 2012, the Company acquired Onyx Research Chemicals Ltd. In May 2012, Tonira Pharma Limited merged with the Company.

Company Address

Ipca Laboratories Ltd

142 AB
Kandivli Industrial Estate Ltd.
Kandivli (West)
MUMBAI     400067
P: +9122.66474747
F: +9122.28686954

Search Stocks